Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosimilar Litigation: Celltrion, Pfizer Claim Victory On Janssen’s Remaining Infringement Claim

Executive Summary

You may also be interested in...



Remicade Patent Fight: Janssen Loses Big, But Pfizer Not Out Of Woods

Pfizer would still be at risk for damages from biosimilar launch if Janssen's manufacturing process patent is upheld even as US Federal Circuit affirms that patent covering Remicade's active ingredient is invalid.

Pfizer v. J&J Sets Stage For Biosimilar Showdown Over Exclusive Contracts

Pfizer's suit claims J&J coerced payers by vowing to withhold all Remicade rebates if any of Pfizer's biosimilar Inflectra is reimbursed, but J&J says Pfizer has failed to show the value of Inflectra.

Pfizer Will Support Inflectra Launch With Dedicated Sales Force

The company is on track to launch the first Remicade biosimilar in the US Nov. 21 using dedicated sales reps and resources from the innovative side of the business, though it will not be a traditional sales force.

Topics

Related Companies

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel